Hospira Recalls Heparin Sodium Bags Due to Sterility Concerns
Hospira is recalling 27,780 bags of Heparin Sodium 2000 USP Units per 1000 mL due to a lack of assurance of sterility and potential leakage from the administrative port.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the rubric specifies that FDA Class II recalls with potential for serious adverse health consequences (such as sterility failure in an IV drug) are rated as Severe (4).
Plain-English summary
Hospira Inc. is recalling 27,780 bags of Heparin Sodium 2000 USP Heparin Units per 1000 mL (2 USP Heparin Units/mL) in 0.9% Sodium Chloride Injection. The product is identified by Lot # 26-125-JT and has an expiration date of 8/14. The recall is being conducted due to a lack of assurance of sterility and the potential for leakage from the administrative port.
The affected product is a prescription-only intravenous medication distributed nationwide, including Puerto Rico. The recall is classified as FDA Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Healthcare providers and facilities should stop using the affected product and contact Hospira for instructions on return or disposal. Patients who have received this product should consult their healthcare provider if they have concerns or experience any adverse effects.
The recalled product
- Product
- HEPARIN SODIUM (HEPARIN SODIUM)
- Brand
- HEPARIN SODIUM
- Manufacturer
- Hospira Inc.
- Category
- Drug — Anticoagulant
- Affected units
- 27,780
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 26-125-JT
- Exp: 8/14
Distribution
Part of a larger recall action
This product is one of 2 recalled by Hospira Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · HEPARIN SODIUM
- ModerateHeparin Sodium Injection Recalled Due to Labeling Issue
FDA (Drugs) · 2023-03-15
- HighHeparin Sodium injectable bags recalled due to potential sterility assurance issues
FDA (Drugs) · 2023-01-11
- SevereHospira Recalls Heparin Sodium Injection Due to Human Hair Particulate
FDA (Drugs) · 2014-12-31
- SevereFresenius Kabi Recalls Heparin Sodium Injection Due to Subpotency
FDA (Drugs) · 2014-03-12
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29